Related Experiment Video

Updated: Jun 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Radiotherapy in locally advanced prostate cancer

Alex Tan1, Chris Parker

  • 1Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK.

Lancet (London, England)
|December 19, 2008
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Use of whole-body MRI to evaluate residual tumour burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer.

The British journal of radiology·2026

Chronic obstructive pulmonary disease: diagnosis, monitoring and chronic management in nursing practice.

British journal of nursing (Mark Allen Publishing)·2026

Recommendations for contouring of gross tumour volume for locally advanced lung cancer using magnetic resonance imaging.

Physics and imaging in radiation oncology·2026

The impact of bladder and rectal dynamics on prostate and seminal vesicles intrafraction motion and deformation in radiotherapy.

Physics and imaging in radiation oncology·2026

Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling study.

Journal of medical economics·2026

Implementation of a Multihospital Electronic Medical Record-Based Insulin Order Set to Reduce Hypoglycemic Events.

AACE endocrinology and diabetes·2025

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Tips and tricks for reducing radiation exposure during retrograde intrarenal surgery: A literature review by the European Association of Urology Section of Endourology.

Asian journal of urology·2026

Correction of image-guided radiotherapy and intrafraction motion using ExacTrac dynamic for head and neck cancer patients.

Technical innovations & patient support in radiation oncology·2026

Comparison of experimental and radiobiological model-predicted survival of human laryngeal squamous cell carcinoma cells in a helium spread-out Bragg peak.

Physics and imaging in radiation oncology·2026

Monte Carlo-based characterization of proton minibeam radiation therapy across clinically relevant beam parameters.

Physics and imaging in radiation oncology·2026

Glycopyrronium Bromide versus Droperidol for Prophylaxis of Postoperative Nausea and Vomiting in Hysteroscopic Day Surgery: A Randomized, Double-Blind, Non-Inferiority Trial.

Drug design, development and therapy·2026

Advanced dose accumulation methods: A comparative study in online adaptive radiotherapy for abdominal-pelvic lymph node oligometastases.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us